---
title: 'Senior Director, Intellectual Property Counsel at Spyre Therapeutics'
canonical: 'https://feeny.ai/job/senior-director-intellectual-property-counsel-spyre-therapeutics-united-states-ecm5dcq7rsyr'
type: 'job'
last_seen: '2026-11-10'
---

# Senior Director, Intellectual Property Counsel at Spyre Therapeutics

- **Company:** Spyre Therapeutics
- **Location:** United States
- **Work type:** remote
- **Posted:** 2026-11-06
- **Last confirmed live:** 2026-11-10
- **Apply:** https://job-boards.greenhouse.io/spyretherapeutics/jobs/5466605008

## Job description

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

Role Summary:

Spyre Therapeutics is seeking an experienced Senior Director, Intellectual Property Counsel, to develop and execute intellectual property strategies that support our pipeline and long-term business objectives. This individual will lead global patent portfolio development, prosecution, and risk assessment, partnering closely with Research, Development, CMC, Clinical, and Business Development. They will also be responsible for trade secret protection and support brand name creation and protection.

This role is intended for a senior IP leader who can become Spyre’s principal intellectual property counsel. The successful candidate will take increasing responsibility for setting company-wide IP priorities, advising executive leadership, and leading the IP function, with the potential to assume Chief Intellectual Property Counsel responsibilities, depending on business needs and performance.

This hands-on role requires strong scientific fluency, sound legal judgment, and the ability to translate complex intellectual property issues into practical recommendations, as well as leadership experience and budget management capability. The successful candidate will bring a combination of law firm and in-house biotechnology experience, with a proactive approach to protecting innovation in a growing organization. Experience should include advising senior business and scientific leaders, managing outside counsel and budgets, and making portfolio and risk-prioritization decisions tied to company objectives.

Key Responsibilities:

IP Strategy and Portfolio Management

- Develop and execute global intellectual property strategies aligned with the company’s pipeline, research priorities, and corporate objectives.
- Build and manage patent portfolios covering drug candidates, formulations, manufacturing processes, methods of use, and other innovations.
- Draft, review, and oversee the preparation and prosecution of U.S. and international patent applications.
- Evaluate invention disclosures and partner with scientists to identify patentable discoveries and develop appropriate filing strategies.
- Identify and ensure protection of trade secrets.
- Conduct and oversee freedom-to-operate, patentability, validity, and infringement analyses; communicate findings and recommend approaches to address identified risks.
- Support life cycle and exclusivity planning, including patent term extension opportunities and coordination with Regulatory and other relevant functions.
- Monitor competitor patent activity and emerging intellectual property developments relevant to the company’s programs.
- Support trademark clearance and protection for product brand names.

Cross-Functional Counseling

- Serve as a trusted intellectual property advisor to discovery, translational science, CMC, clinical development, and other internal teams.
- Translate scientific findings and development plans into actionable patent strategies.
- Review proposed publications, presentations, and other external disclosures to protect intellectual property while supporting scientific communication.
- Provide practical guidance on inventorship, ownership, confidentiality, trade secrets, and intellectual property risks.
- Educate internal stakeholders on intellectual property practices and encourage timely identification and disclosure of inventions.

Transactions and Business Development Support

- Partner with Business Development and Legal colleagues on the intellectual property aspects of licensing, research collaborations, co-development agreements, material transfer agreements, and other strategic transactions.
- Conduct and support intellectual property due diligence for potential partnerships, licensing opportunities, and other business development activities.
- Draft, review, and negotiate intellectual property provisions addressing ownership, prosecution, enforcement, and licensing rights.
- Support intellectual property obligations and governance under existing collaboration and license agreements.

Outside Counsel and Operational Oversight

- Select, direct, and oversee outside patent counsel and other intellectual property service providers globally.
- Ensure patent preparation and prosecution reflect the company’s scientific priorities, business objectives, and quality standards.
- Oversee patent dockets, filing deadlines, annuities, and portfolio records in coordination with external providers.
- Manage intellectual property budgets, forecasts, and outside counsel spending.
- Recommend portfolio prioritization and resource allocation as programs and business needs evolve.

Ideal Candidate:

- J.D. from an accredited law school.
- Active admission to at least one U.S. state bar and registration to practice before the U.S. Patent and Trademark Office.
- At least 12 years of relevant biotechnology or pharmaceutical patent law experience
- Experience at a leading intellectual property law firm and within an in-house biotechnology or pharmaceutical legal department.
- Strong technical understanding of biological and pharmaceutical drug discovery and development, particularly biologics, antibodies, immunology, and inflammation.
- Extensive hands-on experience drafting and prosecuting U.S. and international patent applications and managing complex global patent portfolios.
- Experience with patent disputes, oppositions, or other post-grant proceedings.
- Demonstrated experience conducting freedom-to-operate, patentability, validity, and infringement analyses.
- Experience supporting intellectual property due diligence and negotiating intellectual property provisions in licensing and collaboration agreements.
- Proven ability to oversee outside counsel, manage budgets, and prioritize competing demands.
- Strong communication skills, with the ability to explain complex legal and scientific issues clearly and provide actionable advice.
- Demonstrated ability to work independently, exercise sound judgment, and build effective relationships across scientific and business teams.

## Preferred Qualifications

- In-house experience at an early-stage or rapidly growing biopharmaceutical company.
- Experience supporting antibody therapeutics, combination therapies, and programs in immunology or inflammatory diseases.
- Experience with patent disputes, oppositions, or other post-grant proceedings.

What We Offer:

- Opportunity to work in a fast-paced, dynamic environment where you help shape the culture of our young company, contribute broadly to advance meaningful medicines, and learn quickly.
- Market competitive compensation and benefits package, including base salary, performance bonus, equity grant opportunities, health, welfare & retirement benefits.
- Unlimited PTO
- Two, one-week company-wide shutdowns each
- Commitment to provide professional development opportunities.
- Remote working environment with frequent in-person meetings to address complex problems and build relationships.

The expected salary range offer for this role is $320,000 to $336,000. Actual pay offered may vary depending on job related knowledge, experience, education, and geographic location. As an equal opportunity employer, Spyre is committed to a diverse workforce. Employment decisions regarding recruitment and selection will be made without discrimination based on race, color, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression, veteran status, or other non-job-related characteristics or other prohibited grounds specified in applicable federal, state and local laws. We also embrace differences in experience and background, and welcome diversity of opinions and thought with active recruitment designed to create a stronger and better Spyre that is focused on developing life-changing products for patients.

Spyre Therapeutics, along with other biotech companies, has become aware of a surge in email scams targeting prospective job candidates within our industry. Please be aware that official recruiters at Spyre Therapeutics only use email addresses with the domain “@spyre.com.” We want to also emphasize that we never request candidates to make any purchases or divulge sensitive personal information via email.

Please also be aware that all job postings will be listed on our website at spyre.com/careers/.

## About Spyre Therapeutics

## Company Overview
- **One-liner**: Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation antibody therapies and rational combinations to elevate the standard of care for inflammatory bowel disease (IBD) and other immune-mediated diseases.
- **Entity Type**: Public (NASDAQ: SYRE [ir.spyre.com](https://ir.spyre.com/overview))
- **Headquarters**: Not publicly available (company operates 100% remote with frequent in-person meetings [job-boards.greenhouse.io](https://job-boards.greenhouse.io/spyretherapeutics))
- **Founded**: Not publicly available
- **Founders**: Not publicly available

## Core Business
- **Primary industry/industries**: Biotechnology / Biopharmaceuticals / Immunology
- **Target customers**: B2B (partners, healthcare providers, payers); primarily focused on patients with IBD (Crohn’s disease, ulcerative colitis) and other immune-mediated conditions
- **Mission or purpose statement**: “Develop potentially best-in-class therapeutics for people living with IBD” by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations [spyre.com](https://www.spyre.com/)

## Products & Services
Spyre’s pipeline consists of investigational extended half-life antibodies targeting validated mechanisms, designed for subcutaneous administration and potentially improved efficacy and convenience:
- **SPY001 (α4β7 integrin inhibitor)**: Phase 3-ready anti-integrin antibody with extended half-life; targeting gut-selective inflammation control [spyre.com](https://www.spyre.com/pipeline)
- **SPY120 (TL1A antibody)**: Phase 1/2 anti-TL1A antibody targeting fibrostenotic and inflammatory pathways in IBD [spyre.com](https://www.spyre.com/pipeline)
- **SPY130 (IL-23 antibody)**: Phase 1/2 anti-IL-23 p19 antibody targeting a validated and highly successful mechanism in IBD [spyre.com](https://www.spyre.com/pipeline)
- **SPY002 (α4β7 + TL1A) and SPY003 (α4β7 + IL-23)**: Rational combination programs designed to deliver more complete disease control and greater durability than monotherapy

## Market Standing
- **Valuation/Market Cap**: Not explicitly stated; recent public offering raised substantial capital
- **Key Metric**: **Total Funding via Public Offering**: $463.5 million gross proceeds from a public offering and full exercise of underwriters’ option, announced May 1, 2026 (upsized from $403.0M) [ir.spyre.com](https://ir.spyre.com/overview)
- **Notable Investors/Partners**: The company is publicly traded; institutional and retail investors participated in the offering. Partnership and investor details are disclosed in SEC filings.
- **Growth Signals**:
  - Announced positive **SPY001 Part A Induction Results** on April 14, 2026, demonstrating proof-of-mechanism [ir.spyre.com](https://ir.spyre.com/overview)
  - Raised $463.5M in a single public offering in May 2026, signaling strong institutional confidence
  - Pipeline advancing into Phase 2 and Phase 3 programs across multiple antibody formats
  - Company is rapidly expanding its R&D and clinical capabilities

## Competitive Advantages
- **Rational Combination Strategy**: Spyre is one of the few companies pioneering concurrent targeting of α4β7 with TL1A or IL-23 in a single therapeutic program, potentially offering superior efficacy over single-target biologics
- **Extended Half-Life Antibody Engineering**: All pipeline antibodies are engineered for longer dosing intervals, which could improve patient adherence and convenience
- **100% Remote-First Model**: Operates a fully remote team with periodic in-person gatherings, allowing access to top talent across geographies without requiring relocation
- **Deeply Validated Biology**: All three primary targets (α4β7, TL1A, IL-23) are clinically validated in IBD, derisking the pipeline

## Strategic Focus
- Advance **SPY001** into Phase 3 trials for IBD
- Progress **SPY120** and **SPY130** through Phase 1/2 dose optimization and proof-of-concept studies
- Generate clinical data for the **rational combination programs (SPY002, SPY003)** to demonstrate additive/synergistic benefit
- Leverage the significant capital raise to expand clinical operations, manufacturing, and pipeline expansion

## Why Work Here
- **100% Remote-First Culture**: Spyre is fully remote with “frequent all team, in-person meetings to build relationships and problem solve” [job-boards.greenhouse.io](https://job-boards.greenhouse.io/spyretherapeutics)
- **Generous Time Off**: Unlimited PTO plus two one-week company-wide shutdowns each year
- **Competitive Compensation**: Market-competitive base salary, performance bonus, and equity grant opportunities
- **Comprehensive Benefits**: Health, welfare, and retirement benefits included
- **Fast-Paced Startup Environment**: Opportunities to “wear multiple hats, learn quickly, and help shape the culture of our young company”
- **Mission-Driven**: Direct impact on improving the lives of millions of IBD patients. The team is described as “collaborative and interdisciplinary” [spyre.com](https://www.spyre.com/careers)
- **Transparent and Accessible Leadership**: Company updates and financial results are shared regularly; recent events include public webcasts and presentations

## Sources
1. [spyre.com](https://www.spyre.com/)
2. [ir.spyre.com](https://ir.spyre.com/overview)
3. [job-boards.greenhouse.io](https://job-boards.greenhouse.io/spyretherapeutics)
4. [spyre.com/careers](https://www.spyre.com/careers)
5. [spyre.com/pipeline](https://www.spyre.com/pipeline)

## Other roles at Spyre Therapeutics

- [Clinical Scientist, Clinical Development](https://feeny.ai/job/clinical-scientist-clinical-development-spyre-therapeutics-united-states-21ccy2akc20j) — United States
- [Director, Regulatory Affairs](https://feeny.ai/job/director-regulatory-affairs-spyre-therapeutics-united-states-s1347dxbe7z9) — United States
- [Senior Scientist, Translational Science](https://feeny.ai/job/senior-scientist-translational-science-spyre-therapeutics-united-states-2bxjq71x123q) — United States
- [Director, Drug Safety Physician](https://feeny.ai/job/director-drug-safety-physician-spyre-therapeutics-united-states-34byjx96nsbr) — United States
- [Senior Director, Drug Safety and Pharmacovigilance Operations](https://feeny.ai/job/senior-director-drug-safety-and-pharmacovigilance-operations-spyre-therapeutics-8z5gh0007fj3) — United States